Post-translational Modifications of Immune Checkpoints: Unlocking New Potentials in Cancer Immunotherapy

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2025 Mar 15

PMID 40087690

Authors

Qiongjie Hu

Yueli Shi

Huang Wang

Liuwen Bing

Zhiyong Xu

Affiliations

Soon will be listed here.

Abstract

Immunotherapy targeting immune checkpoints has gained traction across various cancer types in clinical settings due to its notable advantages. Despite this, the overall response rates among patients remain modest, alongside issues of drug resistance and adverse effects. Hence, there is a pressing need to enhance immune checkpoint blockade (ICB) therapies. Post-translational modifications (PTMs) are crucial for protein functionality. Recent research emphasizes their pivotal role in immune checkpoint regulation, directly impacting the expression and function of these key proteins. This review delves into the influence of significant PTMs-ubiquitination, phosphorylation, and glycosylation-on immune checkpoint signaling. By targeting these modifications, novel immunotherapeutic strategies have emerged, paving the way for advancements in optimizing immune checkpoint blockade therapies in the future.

References

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T . Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021; 6(1):72. PMC: 7896069. DOI: 10.1038/s41392-020-00449-4. View

Abril-Rodriguez G, Ribas A . SnapShot: Immune Checkpoint Inhibitors. Cancer Cell. 2017; 31(6):848-848.e1. DOI: 10.1016/j.ccell.2017.05.010. View

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B . Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18(1):10. PMC: 6332843. DOI: 10.1186/s12943-018-0928-4. View

Zhang Y, Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. PMC: 7395159. DOI: 10.1038/s41423-020-0488-6. View

Shebbo S, Binothman N, Darwaish M, Niaz H, Abdulal R, Borjac J . Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy. Front Immunol. 2024; 15:1350208. PMC: 10963412. DOI: 10.3389/fimmu.2024.1350208. View

Suijkerbuijk K, van Eijs M, van Wijk F, Eggermont A . Clinical and translational attributes of immune-related adverse events. Nat Cancer. 2024; 5(4):557-571. DOI: 10.1038/s43018-024-00730-3. View

Shen K, Zhu Y, Xie S, Qin L . Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024; 17(1):25. PMC: 11057182. DOI: 10.1186/s13045-024-01549-2. View

Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S . Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024; 13(1):72. PMC: 11292955. DOI: 10.1186/s40164-024-00539-x. View

10.

Goldtzvik Y, Sen N, Lam S, Orengo C . Protein diversification through post-translational modifications, alternative splicing, and gene duplication. Curr Opin Struct Biol. 2023; 81:102640. DOI: 10.1016/j.sbi.2023.102640. View

11.

Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C . Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024; 13(1):80. PMC: 11301948. DOI: 10.1186/s40164-024-00543-1. View

12.

Hong Z, Liu F, Zhang Z . Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets. Exp Hematol Oncol. 2024; 13(1):91. PMC: 11367865. DOI: 10.1186/s40164-024-00552-0. View

13.

Li C, Lim S, Chung E, Kim Y, Park A, Yao J . Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018; 33(2):187-201.e10. PMC: 5824730. DOI: 10.1016/j.ccell.2018.01.009. View

14.

Li C, Lim S, Xia W, Lee H, Chan L, Kuo C . Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016; 7:12632. PMC: 5013604. DOI: 10.1038/ncomms12632. View

15.

Wang R, He S, Long J, Wang Y, Jiang X, Chen M . Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways. Exp Hematol Oncol. 2024; 13(1):46. PMC: 11040904. DOI: 10.1186/s40164-024-00515-5. View

16.

Leutert M, Entwisle S, Villen J . Decoding Post-Translational Modification Crosstalk With Proteomics. Mol Cell Proteomics. 2021; 20:100129. PMC: 8430371. DOI: 10.1016/j.mcpro.2021.100129. View

17.

Schjoldager K, Narimatsu Y, Joshi H, Clausen H . Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020; 21(12):729-749. DOI: 10.1038/s41580-020-00294-x. View

18.

Jarrold J, Davies C . PRMTs and Arginine Methylation: Cancer's Best-Kept Secret?. Trends Mol Med. 2019; 25(11):993-1009. DOI: 10.1016/j.molmed.2019.05.007. View

19.

Bradley D . The evolution of post-translational modifications. Curr Opin Genet Dev. 2022; 76:101956. DOI: 10.1016/j.gde.2022.101956. View

20.

Wang H, Yang L, Liu M, Luo J . Protein post-translational modifications in the regulation of cancer hallmarks. Cancer Gene Ther. 2022; 30(4):529-547. DOI: 10.1038/s41417-022-00464-3. View